VRDN — Viridian Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $1.76bn
- $1.28bn
- $0.31m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.46 | 1.05 | 2.96 | 1.77 | 0.314 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 46.4 | 111 | 82.7 | 136 | 255 |
Operating Profit | -42 | -110 | -79.7 | -134 | -254 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -41.9 | -111 | -79.4 | -130 | -238 |
Net Income After Taxes | -41.9 | -111 | -79.4 | -130 | -238 |
Net Income Before Extraordinary Items | |||||
Net Income | -41.9 | -111 | -79.4 | -130 | -238 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -41.9 | -111 | -79.4 | -130 | -238 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -19.1 | -11.4 | -6.66 | -4.05 | -5.31 |